Russell Investments Group, Ltd. Otonomy, Inc. Transaction History

Russell Investments Group, Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 10, 2021	SELL	$2.49 - $6.23 $3,513 - $8,790	-1,411 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$3.16 - $4.36 $1,298 - $1,791	411 Added 41.1%	1,411 $5,000
Q3 2019 Nov 01, 2019	SELL	$2.12 - $2.86 $3,180 - $4,290	-1,500 Reduced 60.0%	1,000 $2,000
Q2 2019 Aug 09, 2019	SELL	$2.35 - $3.09 $3,525 - $4,635	-1,500 Reduced 37.5%	2,500 $7,000
Q1 2019 May 13, 2019	BUY	$1.8 - $2.97 $1,260 - $2,079	700 Added 21.21%	4,000 $10,000
Q4 2018 Feb 11, 2019	SELL	$1.51 - $2.93 $2,567 - $4,981	-1,700 Reduced 34.0%	3,300 $6,000
Q3 2018 Oct 26, 2018	SELL	$2.6 - $3.95 $11,180 - $16,985	-4,300 Reduced 46.24%	5,000 $13,000
Q2 2018 Aug 08, 2018	SELL	$3.7 - $4.75 $2,960 - $3,800	-800 Reduced 7.92%	9,300 $36,000
Q1 2018 May 11, 2018	BUY	$4.05 - $6.1 $40,905 - $61,610	10,100 New	10,100 $42,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.